The Mount Sinai Health System, an academic health system in the United States, will adopt the AI-powered Sophia DDM platform from Sophia Genetics, a specialist in AI-driven precision medicine, to advance cancer research and enhance genomic testing capabilities.
Mount Sinai is a National Cancer Institute-designated Comprehensive Cancer Centre in New York City that supports care for over 4,000 oncology patients annually. Mount Sinai’s Molecular Pathology team will utilise Sophia DDM to enhance next-generation sequencing (NGS) capabilities for blood cancers and solid tumours.
Sophia DDM has been designed to enable the detection and interception of a range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.
By combining Mount Sinai’s clinical expertise with Sophia DDM’s AI-powered analytics, the hospital will be able to interpret complex genomic datasets at scale and optimise laboratory resources, enabling teams to focus on direct patient care.
Jane Houldsworth, director of molecular Oncology Pathology of the Mount Sinai Health System, said, “The collaboration between Mount Sinai and Sophia Genetics reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging Sophia DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”
John Carey, managing director, North America, Sophia Genetics, said, “Mount Sinai is widely regarded as one of the world’s leading centres for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honoured to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”
The collaboration was announced at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
